The pharmacokinetics of didanosine were investigated following oral administration of a single 375-mg dose to eight human immunodeficiency virus-seropositive patients with normal renal function and eight human immunodeficiency virus-seropositive uremic patients. In uremic patients, the plasma half-life was longer than that in control patients (respectively, 4.5 2.2 and 1.6 0.4 h). The ratio of total plasma clearance to absolute bioavailability was four-to fivefold lower in uremic patients than in patients with normal renal function (respectively, 491 + 181 and 2,277 + 738 ml/min). Because of the decrease in elimination, concentrations in plasma were higher for uremic patients than for control patients; the maximum concentrations of drug in plasma were, respectively, 3,978 + 1,607 and 1,948 994 ng/ml; the areas under the concentration-time curve were, respectively, 14,050 4,262 and 3,000 956 ng-h/ml. Didanosine was removed by hemodialysis with an extraction ratio of 53% + 8%, a hemodialysis clearance value of 107 21 ml/min, and a fractional drug removal during a 4-h dialysis of 20% 8% of the dose. Dosage adjustments are necessary in uremic patients.
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Didanosine (2',3'-dideoxyinosine) is a purine nucleoside analog with in vitro activity against human immunodeficiency virus (HIV). Didanosine possesses a higher therapeutic ratio than zidovudine (3, 17, 20) . The pharmacokinetics of didanosine were studied in patients with AIDS and AIDSrelated complex during phase I studies (9, 10, 13) ; bioavailability is 35 to 45% for doses of up to 10 mg/kg of body weight and 20 to 25% for doses of over 15 mg/kg; bioavailability is also dependent on oral-dosage forms and on conditions of administration such as the presence of food or antacids (10) . Protein binding is less than 5%, and distribution volume is 50 to 60 liters/70 kg. After intravenous administration, 40 to 70% of the dose is excreted unchanged in urine; elimination is fast, with a half-life (t1/2) of 1.0 to 1.5 h; total plasma clearance (CL) and renal clearance (CLR) are 600 to 800 and 300 to 400 ml/min, respectively. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally.
In recent years, renal manifestations of AIDS and of drug abuse have assumed a particularly important role. Glomerulosclerosis has emerged as a major cause of the nephrotic syndrome and of end-stage renal disease in metropolitan areas with large populations of patients with AIDS and addicts that account for about 10% or more of patients from 18 to 45 years old who are on dialysis programs (4, 6, 18) .
The purpose of this study was to determine the pharmacokinetics of didanosine in patients with severe were collected 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 7.5, and 8 h after drug administration; the 4-h hemodialysis session started 3 h after drug administration. During dialysis, blood samples were obtained each hour from the arterial line entering the dialyzer. In middialysis, an additional venous blood sample leaving the dialyzer was drawn simultaneously with that entering the dialyzer. At this time, the ultrafiltration rate (Q.f) was recorded.
Immediately after blood collection, plasma was separated by centrifugation and stored frozen at -20°C.
Hemodialysis was performed for 4 h every 2 or 3 days with a double-needle access to an arteriovenous fistula and a single-pass dialysate delivery system with a constant dialysate flow rate of 500 ml/min. The blood flow that entered the dialyzer was kept constant between 250 and 300 ml/min. Details of the experimental conditions and the equipment used in the dialysis are given in Table 1 . During dialysis, hemodialysate samples (10 ml each) were obtained each hour.
For control patients, urine samples were collected before drug administration and during 3 periods, 0 to 12, 12 to 24, and 24 to 48 h, after drug administration. Urine samples were buffered with 200 mM potassium phosphate buffer (pH 8) (1 part urine to 2 parts buffer) to improve the stability of didanosine, which hydrolyzes rapidly under even mildly acidic conditions. Dialysate and buffered urine samples were stored frozen at -20°C until analyzed.
Assay method. Concentrations of didanosine in plasma, dialysate, and urine samples were determined by a specific reverse-phase high-performance liquid chromatography assay with detection by UV absorbance after solid-phase extraction according to the method described by Knupp et al. (14) . Didanosine and internal standard (2',3'-didehydro-3'-deoxythymidine) were supplied by Bristol-Myers Squibb Company (Syracuse, N.Y.).
The detection limits for plasma were 20 and 50 ng/ml in control and uremic patients, respectively, and 75 ng/ml for dialysate and 1 ,ug/ml for urine samples. Interday variabilities were 9% for spiked plasma concentrations of 200 and 1,200 ng/ml, 14 and 8% for spiked dialysate concentrations of 250 and 500 ng/ml, and 6 and 9% for spiked urine concentrations of 50 and 250 ,ug/ml. Before analysis, all biological samples were heated at 57°C for 3 h to inactivate the HIV; this process does not alter didanosine (14) .
Pharmacokinetic analysis. The data were analyzed by noncompartmental analysis.
The terminal-phase rate constant (Xz) was determined by linear regression of the natural logarithms of the concentrations in plasma against time for the log-linear elimination phase, typically from 1 or 1.5 h through 8 h in control patients and from 2 or 4 h through 24 h in uremic patients. t1/2(in) are the t1/2s of didanosine between
The results of multiple-dose-simulated kinetics are sumkin is the elimination rate constant during marized in Table 4 : trough, average, and peak concentraely, and r is the length of dialysis (4 h (8) . However, the removal by dialysis is low: the proportion of the pool of didanosine in the body at the start of hemodialysis removed during a 4-h dialysis period was 20% 8% and, as shown Fig. 2 , concentrations in plasma during and between dialysis are close. Consequently, a replacement dose is not necessary and the next scheduled dose should be administered after each dialysis session.
The dialyzability of didanosine is independent of mem- 10 ,uM (3, 17) . Because of the short plasma t1/2, didanosine levels remained in this range for only 2 to 3 h in control patients and for 4 to 6 h in uremic patients after oral administration of 375 mg. Initially, it was believed that continuous intravenous infusion would be necessary to maintain effective levels of didanosine in plasma (9) . However, subsequent studies revealed that dideoxyadenosine triphosphate, the putative metabolite active against HIV reverse transcriptase, has an intracellular t1/2 of 12 to 24 h (1, 11) and that didanosine could be used once or twice daily (2) .
So, on the sole basis of plasma pharmacokinetic data, this single-dose study shows that the dosage regimen of didanosine should be modified in patients with severe renal failure; in patients with normal renal function, the usual dose of didanosine is 375 mg every 12 h ('r). Assuming linear kinetics after multiple administrations, the average steady-state concentration in plasma (Css), given by the formula Css = AUC/T, will be about 250 ng/ml; the predicted Cm, and minimal concentrations in plasma (Cmin) will be 1,721 and 4 ng/ml, respectively. As the plasma drug concentrations are increased in uremic patients, the same dosage regimen will lead to the following increases in the steady-state plasma drug concentrations: Css = 1,171 ng/ml; Cm~, = 4,013 ng/ml; and Cmin = 302 ng/ml. According to Dettli (5) , to maintain the same average steady state in uremic patients as in control patients, the dosage regimen should be decreased by a theoretical factor of 4.7 (ratio of AUC in uremic and control patients). Such a reduction could be obtained with a maintenance dose of 160 mg administered every 24 h. This theoretical dose can be administered easily with the several didanosine dosages marketed either in sachet (45, 67, 100, 167, 250, and 375 mg) or in tablet (10, 25, 50, 100, and 150 mg) form. As shown in Table 4 , a dosage regimen of 150 or 167 mg once a day in uremic patients will lead to concentrations in plasma very close to those observed in control patients with a dosage regimen of 375 mg every 12 h.
Information based on assessments of plasma t1/2 or plasma drug concentrations may not always determine the best dosing schedule, and these dosage recommendations should not be taken as a fixed approach for patients with renal impairment. Rather, the data after a single dose must be extrapolated cautiously to provide recommendations for the adjustment of multiple doses in uremic patients; furthermore, it is not known whether the intracellular pharmacokinetics of didanosine are altered in renal failure.
Because of drug removal by dialysis, didanosine should be administered at the end of a hemodialysis session.
